Evaluation of invasive breast cancer using a 12-chemokine gene expression score (CS): Correlation with clinical outcomes.

A 12-chemokine Gene Signature Is Associated With an Enhanced Cancer-immunity Cycle and Is Relevant for Precision Immunotherapy

“…In previous studies, TLSs presence has been correlated with favorable prognosis in some solid tumors, illustrating their roles in promoting lymphocyte in ltration and increasing the antitumor immune response [11]. Previous studies have proposed various gene signatures of TLSs, among which the 12-chemokine metagene signature has been associated with the presence of TLSs and improved clinical outcomes in colorectal cancer [11], breast cancer [12] and melanoma [13]. Although TLS formation usually indicates an in ammatory context and increased in ltrating T cells in the tumor, the link between the presence of TLSs and each step of the immune cycle…”

“…In melanoma, the combined presence of tumor-associated CD8 + T cells and CD20 + B cells is associated with favorable prognosis, and these CD8 + CD20 + -enriched tumors can be identi ed by immuno uorescence (IF) staining of C-X-C chemokine receptor type 5 (CXCR5) and chemokine C-X-C motif ligand 13 (CXCL13) in combination with CD20 or by quantifying a 9-gene RNA expression signature [10]. In addition, in early methods for TLS detection, expression of a set of lymphoid chemokines (CCL2, CCL3, CCL4, CCL5, CCL8, CCL18, CCL19, CCL21, CXCL9, CXCL10, CXCL11, and CXCL13) called the 12-chemokine TLS signature was also identi ed in multiple cancers, including colorectal cancer, breast cancer, melanoma, and liver cancer [9,[11][12][13].…”